Citius Pharmaceuticals Inc. (NASDAQ:CTXR) saw an upside of 1.36% to close Friday at $0.90 after adding $0.01 on the day. The 5-day average trading volume is 929,800 shares of the company’s common stock. It has gained $0.9699 in the past week and touched a new high 1 time within the past 5 days. An average of 1,681,125 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,724,600.
CTXR’s 1-month performance is -24.04% or -$0.3261 on its low of $0.8500 reached on 08/16/23. The company’s shares have touched a 52-week low of $0.77 and high of $1.71, with the stock’s rally to the 52-week high happening on 04/17/23. YTD, CTXR has achieved 14.42% or $0.1139 and has reached a new high 17 times. However, the current price is down -47.14% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
CTXR stock has a beta of 1.40. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 1.41.
Citius Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 7.10, with the current ratio over the same period at 7.10.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -4.48% to -$8.48 million, while revenue of -$10.53 million was -24.17% off the previous quarter. Analysts expected CTXR to announce -$0.05 per share in earnings in its latest quarter, but it posted -$0.06, representing a -20.00% surprise. EBITDA for the quarter stood at more than -$8.62 million. CTXR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 12.11 million, with total debt at $0.53 million. Shareholders hold equity totaling $158.86 million.
Let’s look briefly at Citius Pharmaceuticals Inc. (CTXR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 39.29% to suggest the stock is trending Neutral, with historical volatility in this time period at 66.35%.
The stock’s 5-day moving average is $0.8897, reflecting a -5.02% or -$0.0478 change from its current price. CTXR is currently trading -22.74% above its 20-day SMA, -11.38% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -29.38% and SMA200 by-16.31%.
Stochastic %K and %D was 18.47% and 13.21% and the average true range (ATR) pointed at 0.0716. The RSI (14) points at 38.30%, while the 14-day stochastic is at 28.53% with the period’s ATR at 0.0748. The stock’s 9-day MACD Oscillator is pointing at -0.0299 and -0.0376 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Citius Pharmaceuticals Inc. (NASDAQ: CTXR), Maxim Group launched coverage with a Buy rating. Analysts offering their rating for CTXR stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CTXR as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is CTXR’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $8.00, with their median price target at $4.00. Looking at these predictions, the average price target given by analysts is for Citius Pharmaceuticals Inc. (CTXR) stock is $5.33.
